[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elderly-patients-gt65-years\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elderly-patients-gt65-years":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100602124","multidisciplinary-dissection-of-renal-and-metabolic-effects-of-glyfozines-on-elderly-patients-from-molecular-aspects-to-clinical-indications-100602124",false,"NCT07119424","Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study;\n2. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.\n3. The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;\n4. Age ≥65 years;\n5. Participant has not yet started the prescribed SGLT2i therapy;\n6. Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.\n\nExclusion Criteria:\n\n1. Current or previous use of SGLT2i;\n2. Inability to sign the informed consent.","ALL","65 Years",{"count":18,"type":19},300,"ESTIMATED","6 Months","OBSERVATIONAL","The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.",[24,25,26,27,28],"Elderly Patients (>65 Years)","Diabetes (DM)","Heart Disease","Renal Diseases","Internal Disease","RECRUITING","2025-08-05",{"date":32,"type":33},"2025-08-13","ACTUAL",{"date":35,"type":33},"2025-02-14",{"date":37,"type":19},"2027-02",{"name":39,"class":40},"Chiara Lanzani","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100599577","electroacupuncture-combined-with-pd-1-inhibitor-for-elderly-patients-with-advanced-nsclc-100599577","NCT07086300","Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC","Clinical Study of Electroacupuncture Combined With PD-1 Inhibitor Treatment for Elderly Patients With Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) confirmed by histopathological or cytological diagnosis.\n* Patients with negative driver gene mutations, as determined by genetic testing or other molecular biological methods, to exclude common driver mutations such as EGFR mutations and ALK rearrangements.\n* Patients aged ≥65 years, with consideration for the patients' overall physical condition. Additional assessments will be conducted if there are comorbidities or other factors that may affect their physical status.\n* PD-L1 tumor proportion score (TPS) ≥1%.\n* Estimated survival time \\>3 months, as determined by clinical evaluation based on the patient's overall condition, tumor progression, and response to treatment.\n* ECOG performance status score of 0-2.\n* Patients with good treatment compliance, who are willing to sign an informed consent form, indicating their understanding and agreement to adhere to the study protocol for treatment and follow-up.\n\nExclusion Criteria:\n\n* Patients with a history of or concurrent other malignancies within the past 5 years.\n* Patients with severe organ dysfunction or other serious comorbidities, such as heart failure (NYHA Class III-IV), hepatic or renal insufficiency, as assessed by routine examinations including liver function tests, renal function tests, and electrocardiograms.\n* Patients with untreated central nervous system metastases. Only those who have undergone at least one course of systemic or surgical treatment and have been confirmed to have stable disease by imaging studies will be included.\n* Patients with psychiatric disorders, including a history of severe mental illnesses (e.g., schizophrenia, bipolar disorder) that require pharmacological treatment for control.\n* Patients with a history of multiple drug allergies or an allergic constitution, particularly those who have experienced severe allergic reactions such as anaphylactic shock or allergic rashes.\n* Patients with active autoimmune diseases or infectious diseases, including but not limited to active or chronic viral hepatitis, active pulmonary tuberculosis, or other infectious or autoimmune conditions deemed by the clinical investigator to potentially affect the study.\n* Patients who are pregnant or breastfeeding.","100 Years",{"count":51,"type":19},120,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a multicenter, randomized controlled clinical trial. The main question it aims to answer is: the combination of electroacupuncture and PD-1 inhibitor therapy has demonstrated significant improvements in both clinical efficacy and safety profiles among elderly patients with advanced NSCLC. Researchers will compare a sham electroacupuncture group combined with PD-1 inhibitor therapy (serving as the control group) to see if the intervention group exhibits superior therapeutic efficacy and safety outcomes. Participants will be randomly assigned to one of two groups: an electroacupuncture combined with an immune checkpoint inhibitor group, or a sham electroacupuncture combined with an immune checkpoint inhibitor group. The immune checkpoint inhibitor will be administered on a 21-day cycle, with a total of 4 to 6 treatment cycles, followed by the option for maintenance therapy. Electroacupuncture treatment will commence on the same day as the initiation of the immune checkpoint inhibitor cycle, administered once daily for a total of five sessions per cycle, with 4 to 6 cycles in total. The primary outcome measure is progression-free survival (PFS). Secondary outcomes include objective response rate (ORR), quality of life, immune function, traditional Chinese medicine syndrome scores for lung cancer, and safety parameters. This study aims to establish the efficacy and safety of electroacupuncture combined with PD-1 inhibitors in elderly patients with advanced NSCLC. Additionally, peripheral non-coding RNA will be collected at baseline to analyze differentially expressed genes, thereby identifying molecular predictive biomarkers for patients who may benefit most from this combined treatment approach.",[24,57,58,59],"Non-Small Cell Lung Cancer","PD-1 Inhibitors","Electroacupuncture",[61,62,63,64,65],"electroacupuncture","Elderly patients","non-small cell lung cancer","Immunotherapy","immune checkpoint inhibitor","2025-07-18",{"date":68,"type":33},"2025-07-25",{"date":70,"type":33},"2025-07-08",{"date":72,"type":19},"2028-12-31",{"name":74,"class":40},"Kong Fanming",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100590941","low--vs-normal-flow-anesthesia-and-delirium-after-hip-fracture-in-the-elderly-100590941","NCT06973967","Low- vs. Normal-Flow Anesthesia and Delirium After Hip Fracture in the Elderly","Evaluation of the Association Between Low-Flow and Normal-Flow Anesthesia and Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery","Inclusion Criteria:\n\nPatients aged 65 years and older who are scheduled to undergo surgical treatment for hip fracture, classified as ASA physical status I-IV, and who have signed the informed consent form will be included in the study.\n\nExclusion Criteria:\n\nPatients with complex fractures (multiple fractures, extremity, abdominal, pelvic or sacral trauma, head trauma, etc.), those with relative contraindications to general anesthesia (e.g., known difficult airway, malignant hyperthermia), patients requiring postoperative intubated intensive care follow-up, those with a history of dementia, sleep disorders, or psychosis, individuals with serious neurological diseases (e.g., Parkinson's disease, stroke sequelae), those with a history of opioid, alcohol, or substance use, patients with cerebrovascular disease, those who underwent surgery within the past 6 months, patients with hearing or vision impairment, bleeding disorders or those taking medications affecting coagulation, patients with hypoalbuminemia (\\\u003C3 g\u002FdL), preoperative anemia with hematocrit \\\u003C30%, known allergy to anesthetic drugs, severe cardiopulmonary failure, immobility, malnutrition, or those who are unable to comply with the study protocol will be excluded from the study.",{"count":83,"type":19},128,"The aim of this study is to investigate the relationship between low-flow and normal-flow anesthesia techniques and the development of postoperative delirium in elderly patients undergoing surgery for hip fracture.",[86,87,24,88],"Delirium - Postoperative","Low Flow Anesthesia","Hip Surgery",[90,91,92,93],"delirium","hip surgery","elderly patients","low-flow anesthesia","NOT_YET_RECRUITING","2025-05-14",{"date":97,"type":33},"2025-05-15",{"date":99,"type":19},"2025-05-08",{"date":101,"type":19},"2025-08-07",{"name":103,"class":104},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV"]